Ligand Pharmaceuticals (LGND) Total Liabilities (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Total Liabilities data on file, last reported at $534.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 386.6% year-over-year to $534.8 million; the trailing twelve-month figure through Mar 2026 stood at $534.8 million (up 386.6% YoY), and the FY2025 full-year result was $543.4 million, up 388.1% from the prior year.
• Total Liabilities eased to $534.8 million in Q1 2026, from $543.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $543.4 million in Q4 2025 to a low of $86.3 million in Q4 2023.
• A 5-year average of $217.0 million and a median of $120.1 million in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities plunged 65.97% in 2023 and jumped 388.1% in 2025, its largest moves.
• Tracing LGND's Total Liabilities over 5 years: stood at $165.2 million in 2022, then plunged by 47.75% to $86.3 million in 2023, then grew by 29.0% to $111.3 million in 2024, then jumped by 388.1% to $543.4 million in 2025, then declined by 1.59% to $534.8 million in 2026.
• Business Quant data shows LGND's Total Liabilities at $534.8 million in Q1 2026, $543.4 million in Q4 2025, and $526.6 million in Q3 2025.